Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-117,700
Closed -$23.2M 1232
2024
Q3
$23.2M Buy
117,700
+7,300
+7% +$1.36M 0.05% 221
2024
Q2
$18.9M Buy
110,400
+32,200
+41% +$5.33M 0.04% 274
2024
Q1
$14.2M Sell
78,200
-21,700
-22% -$3.74M 0.03% 367
2023
Q4
$15.5M Sell
99,900
-43,900
-31% -$6.4M 0.03% 426
2023
Q3
$21.4M Buy
+143,800
New +$21.1M 0.04% 309

Other funds holding ABBV

GTS Securities's ABBV Position: Q1 2026 in Review

GTS Securities reduced its AbbVie (ABBV) stake by 66% in Q1 2026, selling an estimated $2.74M and leaving 6,393 shares worth $1.39M. The position accounts for 0.05% of the portfolio, ranked #282.

GTS Securities first reported a position in ABBV in Q3 2023 and has held it in 11 quarters since. The position peaked at $14.7M in Q4 2023. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • GTS Securities held 6,393 shares of AbbVie worth $1.39M as of Q1 2026.
  • GTS Securities sold 12,357 AbbVie shares in Q1 2026, an estimated $2.74M.
  • AbbVie made up 0.05% of GTS Securities's portfolio in Q1 2026, its #282 holding.
  • GTS Securities first reported a position in AbbVie in Q3 2023 and has held it in 11 quarters since.
  • GTS Securities's AbbVie position peaked at $14.7M in Q4 2023.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.